Sugi Predict

Sugi Predict / Targets / PIK3R4

PIK3R4

Phosphoinositide 3-kinase regulatory subunit 4 · Q99570 · PIK3R4 on Sugi Atlas →

94 patent compounds predicted against PIK3R4, 71 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9957245 SCHEMBL9957245 1.00 1/20
SCHEMBL29394375 SCHEMBL29394375 1.00 1/20
SCHEMBL9957247 SCHEMBL9957247 0.82 1/20
SCHEMBL9957623 SCHEMBL9957623 0.81 1/20
SCHEMBL9957785 SCHEMBL9957785 0.76 1/20
SCHEMBL9956230 SCHEMBL9956230 0.72 1/20
SCHEMBL9957195 SCHEMBL9957195 0.72 1/20
SCHEMBL9957794 SCHEMBL9957794 0.71 1/20
SCHEMBL9956997 SCHEMBL9956997 0.69 1/20
SCHEMBL9957109 SCHEMBL9957109 0.67 1/20
SCHEMBL9957099 SCHEMBL9957099 0.65 1/20
SCHEMBL16390643 SCHEMBL16390643 0.62 1/20
SCHEMBL9957031 SCHEMBL9957031 0.60 1/20
SCHEMBL9956658 SCHEMBL9956658 0.60 1/20
SCHEMBL9957481 SCHEMBL9957481 0.60 1/20
SCHEMBL16390620 SCHEMBL16390620 0.59 1/20
SCHEMBL16390921 SCHEMBL16390921 0.59 1/20
SCHEMBL9956548 SCHEMBL9956548 0.57 1/20
SCHEMBL9957553 SCHEMBL9957553 0.57 1/20
SCHEMBL16390988 SCHEMBL16390988 0.57 1/20

Clinical trials — most relevant to PIK3R4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adjuvant Low Dose Aspirin in Colorectal Cancer PHASE3ACTIVE_NOT_RECRUITING
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations PHASE3COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian PHASE1ACTIVE_NOT_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive? nanUNKNOWN
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies nanNOT_YET_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIK3R4 binder may also engage these)

ProteinNameSimilarity
Q5R9I3 — 1.000 Q5R9I3 →
Q8VD65 — 1.000 Q8VD65 →
P0C0R5 — 0.999 P0C0R5 →
Q9M0E5 — 0.996 Q9M0E5 →
Q06708 — 0.989 Q06708 →
P87145 — 0.989 P87145 →
PPP2R5D Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform 0.988 landscape →
Q5R629 — 0.988 Q5R629 →
Q28653 — 0.988 Q28653 →
Q2KI89 — 0.988 Q2KI89 →
Q66L58 — 0.988 Q66L58 →
E0W1I1 — 0.988 E0W1I1 →
Q8RW96 — 0.988 Q8RW96 →
Q68F38 — 0.988 Q68F38 →
Q8BX57 — 0.987 Q8BX57 →
Q9UVG6 — 0.987 Q9UVG6 →
A4FV68 — 0.987 A4FV68 →
Q5NBT9 — 0.987 Q5NBT9 →
Q6FRH8 — 0.987 Q6FRH8 →
Q16537 — 0.987 Q16537 →
Q6PD03 — 0.987 Q6PD03 →
P70600 — 0.987 P70600 →
Q5XHF8 — 0.986 Q5XHF8 →
Q14D04 — 0.986 Q14D04 →
Q9W3E1 — 0.986 Q9W3E1 →
O54774 — 0.986 O54774 →
Q6IDD9 — 0.986 Q6IDD9 →
A0A2R8QPS5 — 0.986 A0A2R8QPS5 →
PPP2R5A Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform 0.986 landscape →
A0JMA8 — 0.986 A0JMA8 →